CEACAM5-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
labetuzumab govitecan (IMMU-130) / Gilead
ACTRN12623001333606: Investigating the efficacy of an Adjuvant immunotherapy for preventing colorectal liver metastases - The CCaLM trial

Not yet recruiting
2
66
 
St George Hospital, St George Hospital (Trust Fund - Prof David Morris)
Colon cancer
 
 
tusamitamab ravtansine (SAR408701) / Sanofi, AbbVie
CARMEN-LC03, NCT04154956 / 2019-001273-81: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Jul 2023 - Dec 2023: Interim analysis data from CARMEN-LC03 trial for 2L/3L non-squamous NSCLC
Active, not recruiting
3
389
Europe, Canada, Japan, US, RoW
SAR408701, Docetaxel, TAXOTERE
Sanofi
Non-small Cell Lung Cancer Metastatic
09/23
06/25
2021-004423-32: Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEA

Ongoing
2
45
Europe
Tusamitamab ravtansine, SAR408701, Concentrate for solution for infusion
Sanofi Aventis Recherche & Développement, Sanofi Aventis Recherche & Développement
Non-squamous non-small-cell lung cancer, Lung cancer, Diseases [C] - Cancer [C04]
 
 
CARMEN-GC01, NCT05071053 / 2021-001967-26: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-GC01 trial in combination with ramucirumab for advanced gastric or gastroesophageal junction
Active, not recruiting
2
35
Europe, Japan, RoW
Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701)
Sanofi
Adenocarcinoma Gastric, Gastrooesophageal Cancer
06/23
12/24
NCT05849246: The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Terminated
2
4
RoW
Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed, Sintilimab+Carboplatin or Cisplatin+Pemetrexed, Tusamitamab ravtansine+Sintilimab
Innovent Biologics (Suzhou) Co. Ltd.
Non-squamous Non-small-cell Lung Cancer
11/23
12/23
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Active, not recruiting
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
CARMEN-BT01, NCT04659603 / 2020-003096-18: Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Active, not recruiting
2
50
Europe, US, RoW
tusamitamab ravtansine, SAR408701, Gemcitabine
Sanofi
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
02/24
11/24
CARMEN-LC06, NCT05245071 / 2021-004423-32: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Terminated
2
22
Europe, Japan, US, RoW
Tusamitamab ravtansine, SAR408701
Sanofi, Sanofi Aventis Recherche & Développement
Non-squamous Non-small Cell Lung Cancer
03/24
11/24
CARMEN-LC04, NCT04394624 / 2019-003914-15: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2021 : Data from CARMEN-LC04 trial in combination with ramucirumab for NSCLC
Terminated
2
31
Europe, US, RoW
SAR408701, ramucirumab, pembrolizumab
Sanofi
Non-small Cell Lung Cancer Metastatic
03/23
10/24
INTRUSION, NCT05703555 / 2022-003451-34: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

Withdrawn
2
60
Europe
Tusamitamab ravtansine, SAR408701
Erasmus Medical Center, Sanofi
Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer
02/24
02/24
CEACAM5, NCT02187848: Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Checkmark Data for advanced solid tumors at ASCO 2020
Jun 2020 - Jun 2020: Data for advanced solid tumors at ASCO 2020
Terminated
1
254
Europe, Canada, US, RoW
SAR408701
Sanofi
Neoplasm Malignant
11/20
11/24
TusaRav-QT, NCT05429762: Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Terminated
1
56
Europe, US, RoW
Tusamitamab ravtansine, SAR408701
Sanofi
Neoplasm
08/23
04/24
A2B530 / A2 Biotherap
EVEREST-1, NCT05736731: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants with Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Recruiting
1/2
160
US
A2B530, Tmod CAR T-cell Therapy, xT-Onco with HLA-LOH Assay
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
12/26
12/28
PF-08046050 / Sanofi, Pfizer
SGNCEA5C-001, NCT06131840: A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting
1
410
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/29
03/30
precemtabart tocentecan (M9140) / EMD Serono
PROCEADE PanTumor, NCT06710132: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors

Not yet recruiting
1/2
250
Europe, US
M9140
EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany
Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
01/29
01/29
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Canada, Japan, US, RoW
M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
EBC-129 / A*Star, National Cancer Centre Singapore
EBC-129-01, NCT05701527: A Study of EBC-129 in Advanced Solid Tumours

Recruiting
1
84
US, RoW
EBC-129, Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities, Parexel
Advanced Solid Tumours
06/26
06/26
TB-ADC-02 / Theragen Bio
No trials found

Download Options